NEW YORK (GenomeWeb) – Sigma-Aldrich said in its Form 10-K recently that it paid about $170 million in cash for Cell Marque, a provider of in vitro diagnostic antibody reagents and kits.
Sigma-Aldrich acquired Cell Marque in late October but did not disclose the acquisition price at the time. In its document filed with the US Securities Exchange Commission, it estimated the preliminary allocation of the total purchase price consideration at $17 million for net operating assets; $66 million for intangible assets, consisting primarily of customer relationships; and $87 million for goodwill. Sigma-Aldrich added that Cell Marque did not have a material impact on its 2014 earnings.
Sigma-Aldrich is currently in the process of being acquired by Merck KGaA for $17 billion. The deal is anticipated to be completed by mid-year.